

# COVID-19 Impact on Global Immunomodulator for Multiple Myeloma Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C499B4347FD8EN.html>

Date: July 2020

Pages: 98

Price: US\$ 3,900.00 (Single User License)

ID: C499B4347FD8EN

## Abstracts

This report focuses on the global Immunomodulator for Multiple Myeloma status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immunomodulator for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Celgene

Exova

Natco Pharma

Intas Pharmaceuticals

Indiabulls Pharmaceutical

Cipla

Glenmark Pharmaceuticals

Dr Reddy's Laboratories

Qilu Pharmaceutical

Chia Tai-Tianqing

Hanson Pharm

Meidakang Huakang Pharmaceutical

Shandong Kongfu Pharmaceutical

Market segment by Type, the product can be split into

Thalidomide

Lenalidomide

Pomalidomide

Other

Market segment by Application, split into

Hospital

Drug Center

Clinic

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Immunomodulator for Multiple Myeloma status, future forecast, growth opportunity, key market and key players.

To present the Immunomodulator for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Immunomodulator for Multiple Myeloma are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

## Contents

### 1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Immunomodulator for Multiple Myeloma Revenue
- 1.4 Market Analysis by Type
  - 1.4.1 Global Immunomodulator for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
  - 1.4.2 Thalidomide
  - 1.4.3 Lenalidomide
  - 1.4.4 Pomalidomide
  - 1.4.5 Other
- 1.5 Market by Application
  - 1.5.1 Global Immunomodulator for Multiple Myeloma Market Share by Application: 2020 VS 2026
  - 1.5.2 Hospital
  - 1.5.3 Drug Center
  - 1.5.4 Clinic
  - 1.5.5 Other
- 1.6 Coronavirus Disease 2019 (Covid-19): Immunomodulator for Multiple Myeloma Industry Impact
  - 1.6.1 How the Covid-19 is Affecting the Immunomodulator for Multiple Myeloma Industry
    - 1.6.1.1 Immunomodulator for Multiple Myeloma Business Impact Assessment - Covid-19
    - 1.6.1.2 Supply Chain Challenges
    - 1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
  - 1.6.2 Market Trends and Immunomodulator for Multiple Myeloma Potential Opportunities in the COVID-19 Landscape
  - 1.6.3 Measures / Proposal against Covid-19
    - 1.6.3.1 Government Measures to Combat Covid-19 Impact
    - 1.6.3.2 Proposal for Immunomodulator for Multiple Myeloma Players to Combat Covid-19 Impact
- 1.7 Study Objectives
- 1.8 Years Considered

### 2 GLOBAL GROWTH TRENDS BY REGIONS

- 2.1 Immunomodulator for Multiple Myeloma Market Perspective (2015-2026)
- 2.2 Immunomodulator for Multiple Myeloma Growth Trends by Regions
  - 2.2.1 Immunomodulator for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
  - 2.2.2 Immunomodulator for Multiple Myeloma Historic Market Share by Regions (2015-2020)
  - 2.2.3 Immunomodulator for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
  - 2.3.1 Market Top Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Challenges
  - 2.3.4 Porter's Five Forces Analysis
  - 2.3.5 Immunomodulator for Multiple Myeloma Market Growth Strategy
  - 2.3.6 Primary Interviews with Key Immunomodulator for Multiple Myeloma Players (Opinion Leaders)

### **3 COMPETITION LANDSCAPE BY KEY PLAYERS**

- 3.1 Global Top Immunomodulator for Multiple Myeloma Players by Market Size
  - 3.1.1 Global Top Immunomodulator for Multiple Myeloma Players by Revenue (2015-2020)
  - 3.1.2 Global Immunomodulator for Multiple Myeloma Revenue Market Share by Players (2015-2020)
  - 3.1.3 Global Immunomodulator for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Immunomodulator for Multiple Myeloma Market Concentration Ratio
  - 3.2.1 Global Immunomodulator for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
  - 3.2.2 Global Top 10 and Top 5 Companies by Immunomodulator for Multiple Myeloma Revenue in 2019
- 3.3 Immunomodulator for Multiple Myeloma Key Players Head office and Area Served
- 3.4 Key Players Immunomodulator for Multiple Myeloma Product Solution and Service
- 3.5 Date of Enter into Immunomodulator for Multiple Myeloma Market
- 3.6 Mergers & Acquisitions, Expansion Plans

### **4 BREAKDOWN DATA BY TYPE (2015-2026)**

4.1 Global Immunomodulator for Multiple Myeloma Historic Market Size by Type (2015-2020)

4.2 Global Immunomodulator for Multiple Myeloma Forecasted Market Size by Type (2021-2026)

## **5 IMMUNOMODULATOR FOR MULTIPLE MYELOMA BREAKDOWN DATA BY APPLICATION (2015-2026)**

5.1 Global Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020)

5.2 Global Immunomodulator for Multiple Myeloma Forecasted Market Size by Application (2021-2026)

## **6 NORTH AMERICA**

6.1 North America Immunomodulator for Multiple Myeloma Market Size (2015-2020)

6.2 Immunomodulator for Multiple Myeloma Key Players in North America (2019-2020)

6.3 North America Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020)

6.4 North America Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020)

## **7 EUROPE**

7.1 Europe Immunomodulator for Multiple Myeloma Market Size (2015-2020)

7.2 Immunomodulator for Multiple Myeloma Key Players in Europe (2019-2020)

7.3 Europe Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020)

7.4 Europe Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020)

## **8 CHINA**

8.1 China Immunomodulator for Multiple Myeloma Market Size (2015-2020)

8.2 Immunomodulator for Multiple Myeloma Key Players in China (2019-2020)

8.3 China Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020)

8.4 China Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020)

## **9 JAPAN**

- 9.1 Japan Immunomodulator for Multiple Myeloma Market Size (2015-2020)
- 9.2 Immunomodulator for Multiple Myeloma Key Players in Japan (2019-2020)
- 9.3 Japan Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020)
- 9.4 Japan Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020)

## **10 SOUTHEAST ASIA**

- 10.1 Southeast Asia Immunomodulator for Multiple Myeloma Market Size (2015-2020)
- 10.2 Immunomodulator for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020)
- 10.4 Southeast Asia Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020)

## **11 INDIA**

- 11.1 India Immunomodulator for Multiple Myeloma Market Size (2015-2020)
- 11.2 Immunomodulator for Multiple Myeloma Key Players in India (2019-2020)
- 11.3 India Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020)
- 11.4 India Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020)

## **12 CENTRAL & SOUTH AMERICA**

- 12.1 Central & South America Immunomodulator for Multiple Myeloma Market Size (2015-2020)
- 12.2 Immunomodulator for Multiple Myeloma Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020)
- 12.4 Central & South America Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020)

## **13 KEY PLAYERS PROFILES**

- 13.1 Celgene

- 13.1.1 Celgene Company Details
- 13.1.2 Celgene Business Overview and Its Total Revenue
- 13.1.3 Celgene Immunomodulator for Multiple Myeloma Introduction
- 13.1.4 Celgene Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020))
- 13.1.5 Celgene Recent Development
- 13.2 Exova
  - 13.2.1 Exova Company Details
  - 13.2.2 Exova Business Overview and Its Total Revenue
  - 13.2.3 Exova Immunomodulator for Multiple Myeloma Introduction
  - 13.2.4 Exova Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020)
  - 13.2.5 Exova Recent Development
- 13.3 Natco Pharma
  - 13.3.1 Natco Pharma Company Details
  - 13.3.2 Natco Pharma Business Overview and Its Total Revenue
  - 13.3.3 Natco Pharma Immunomodulator for Multiple Myeloma Introduction
  - 13.3.4 Natco Pharma Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020)
  - 13.3.5 Natco Pharma Recent Development
- 13.4 Intas Pharmaceuticals
  - 13.4.1 Intas Pharmaceuticals Company Details
  - 13.4.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
  - 13.4.3 Intas Pharmaceuticals Immunomodulator for Multiple Myeloma Introduction
  - 13.4.4 Intas Pharmaceuticals Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020)
  - 13.4.5 Intas Pharmaceuticals Recent Development
- 13.5 Indiabulls Pharmaceutical
  - 13.5.1 Indiabulls Pharmaceutical Company Details
  - 13.5.2 Indiabulls Pharmaceutical Business Overview and Its Total Revenue
  - 13.5.3 Indiabulls Pharmaceutical Immunomodulator for Multiple Myeloma Introduction
  - 13.5.4 Indiabulls Pharmaceutical Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020)
  - 13.5.5 Indiabulls Pharmaceutical Recent Development
- 13.6 Cipla
  - 13.6.1 Cipla Company Details
  - 13.6.2 Cipla Business Overview and Its Total Revenue
  - 13.6.3 Cipla Immunomodulator for Multiple Myeloma Introduction
  - 13.6.4 Cipla Revenue in Immunomodulator for Multiple Myeloma Business



(2015-2020)

13.6.5 Cipla Recent Development

13.7 Glenmark Pharmaceuticals

13.7.1 Glenmark Pharmaceuticals Company Details

13.7.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue

13.7.3 Glenmark Pharmaceuticals Immunomodulator for Multiple Myeloma Introduction

13.7.4 Glenmark Pharmaceuticals Revenue in Immunomodulator for Multiple Myeloma

Business (2015-2020)

13.7.5 Glenmark Pharmaceuticals Recent Development

13.8 Dr Reddy's Laboratories

13.8.1 Dr Reddy's Laboratories Company Details

13.8.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue

13.8.3 Dr Reddy's Laboratories Immunomodulator for Multiple Myeloma Introduction

13.8.4 Dr Reddy's Laboratories Revenue in Immunomodulator for Multiple Myeloma

Business (2015-2020)

13.8.5 Dr Reddy's Laboratories Recent Development

13.9 Qilu Pharmaceutical

13.9.1 Qilu Pharmaceutical Company Details

13.9.2 Qilu Pharmaceutical Business Overview and Its Total Revenue

13.9.3 Qilu Pharmaceutical Immunomodulator for Multiple Myeloma Introduction

13.9.4 Qilu Pharmaceutical Revenue in Immunomodulator for Multiple Myeloma

Business (2015-2020)

13.9.5 Qilu Pharmaceutical Recent Development

13.10 Chia Tai-Tianqing

13.10.1 Chia Tai-Tianqing Company Details

13.10.2 Chia Tai-Tianqing Business Overview and Its Total Revenue

13.10.3 Chia Tai-Tianqing Immunomodulator for Multiple Myeloma Introduction

13.10.4 Chia Tai-Tianqing Revenue in Immunomodulator for Multiple Myeloma

Business (2015-2020)

13.10.5 Chia Tai-Tianqing Recent Development

13.11 Hanson Pharm

10.11.1 Hanson Pharm Company Details

10.11.2 Hanson Pharm Business Overview and Its Total Revenue

10.11.3 Hanson Pharm Immunomodulator for Multiple Myeloma Introduction

10.11.4 Hanson Pharm Revenue in Immunomodulator for Multiple Myeloma Business

(2015-2020)

10.11.5 Hanson Pharm Recent Development

13.12 Meidakang Huakang Pharmaceutical

10.12.1 Meidakang Huakang Pharmaceutical Company Details

10.12.2 Meidakang Huakang Pharmaceutical Business Overview and Its Total Revenue

10.12.3 Meidakang Huakang Pharmaceutical Immunomodulator for Multiple Myeloma Introduction

10.12.4 Meidakang Huakang Pharmaceutical Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020)

10.12.5 Meidakang Huakang Pharmaceutical Recent Development

13.13 Shandong Kongfu Pharmaceutical

10.13.1 Shandong Kongfu Pharmaceutical Company Details

10.13.2 Shandong Kongfu Pharmaceutical Business Overview and Its Total Revenue

10.13.3 Shandong Kongfu Pharmaceutical Immunomodulator for Multiple Myeloma Introduction

10.13.4 Shandong Kongfu Pharmaceutical Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020)

10.13.5 Shandong Kongfu Pharmaceutical Recent Development

## **14 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **15 APPENDIX**

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Immunomodulator for Multiple Myeloma Key Market Segments

Table 2. Key Players Covered: Ranking by Immunomodulator for Multiple Myeloma Revenue

Table 3. Ranking of Global Top Immunomodulator for Multiple Myeloma Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Immunomodulator for Multiple Myeloma Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Thalidomide

Table 6. Key Players of Lenalidomide

Table 7. Key Players of Pomalidomide

Table 8. Key Players of Other

Table 9. COVID-19 Impact Global Market: (Four Immunomodulator for Multiple Myeloma Market Size Forecast Scenarios)

Table 10. Opportunities and Trends for Immunomodulator for Multiple Myeloma Players in the COVID-19 Landscape

Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 12. Key Regions/Countries Measures against Covid-19 Impact

Table 13. Proposal for Immunomodulator for Multiple Myeloma Players to Combat Covid-19 Impact

Table 14. Global Immunomodulator for Multiple Myeloma Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 15. Global Immunomodulator for Multiple Myeloma Market Size by Regions (US\$ Million): 2020 VS 2026

Table 16. Global Immunomodulator for Multiple Myeloma Market Size by Regions (2015-2020) (US\$ Million)

Table 17. Global Immunomodulator for Multiple Myeloma Market Share by Regions (2015-2020)

Table 18. Global Immunomodulator for Multiple Myeloma Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 19. Global Immunomodulator for Multiple Myeloma Market Share by Regions (2021-2026)

Table 20. Market Top Trends

Table 21. Key Drivers: Impact Analysis

Table 22. Key Challenges

Table 23. Immunomodulator for Multiple Myeloma Market Growth Strategy

Table 24. Main Points Interviewed from Key Immunomodulator for Multiple Myeloma Players

Table 25. Global Immunomodulator for Multiple Myeloma Revenue by Players (2015-2020) (Million US\$)

Table 26. Global Immunomodulator for Multiple Myeloma Market Share by Players (2015-2020)

Table 27. Global Top Immunomodulator for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immunomodulator for Multiple Myeloma as of 2019)

Table 28. Global Immunomodulator for Multiple Myeloma by Players Market Concentration Ratio (CR5 and HHI)

Table 29. Key Players Headquarters and Area Served

Table 30. Key Players Immunomodulator for Multiple Myeloma Product Solution and Service

Table 31. Date of Enter into Immunomodulator for Multiple Myeloma Market

Table 32. Mergers & Acquisitions, Expansion Plans

Table 33. Global Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 34. Global Immunomodulator for Multiple Myeloma Market Size Share by Type (2015-2020)

Table 35. Global Immunomodulator for Multiple Myeloma Revenue Market Share by Type (2021-2026)

Table 36. Global Immunomodulator for Multiple Myeloma Market Size Share by Application (2015-2020)

Table 37. Global Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 38. Global Immunomodulator for Multiple Myeloma Market Size Share by Application (2021-2026)

Table 39. North America Key Players Immunomodulator for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 40. North America Key Players Immunomodulator for Multiple Myeloma Market Share (2019-2020)

Table 41. North America Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 42. North America Immunomodulator for Multiple Myeloma Market Share by Type (2015-2020)

Table 43. North America Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 44. North America Immunomodulator for Multiple Myeloma Market Share by

Application (2015-2020)

Table 45. Europe Key Players Immunomodulator for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 46. Europe Key Players Immunomodulator for Multiple Myeloma Market Share (2019-2020)

Table 47. Europe Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 48. Europe Immunomodulator for Multiple Myeloma Market Share by Type (2015-2020)

Table 49. Europe Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 50. Europe Immunomodulator for Multiple Myeloma Market Share by Application (2015-2020)

Table 51. China Key Players Immunomodulator for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 52. China Key Players Immunomodulator for Multiple Myeloma Market Share (2019-2020)

Table 53. China Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 54. China Immunomodulator for Multiple Myeloma Market Share by Type (2015-2020)

Table 55. China Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 56. China Immunomodulator for Multiple Myeloma Market Share by Application (2015-2020)

Table 57. Japan Key Players Immunomodulator for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 58. Japan Key Players Immunomodulator for Multiple Myeloma Market Share (2019-2020)

Table 59. Japan Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 60. Japan Immunomodulator for Multiple Myeloma Market Share by Type (2015-2020)

Table 61. Japan Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 62. Japan Immunomodulator for Multiple Myeloma Market Share by Application (2015-2020)

Table 63. Southeast Asia Key Players Immunomodulator for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 64. Southeast Asia Key Players Immunomodulator for Multiple Myeloma Market Share (2019-2020)

Table 65. Southeast Asia Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 66. Southeast Asia Immunomodulator for Multiple Myeloma Market Share by Type (2015-2020)

Table 67. Southeast Asia Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 68. Southeast Asia Immunomodulator for Multiple Myeloma Market Share by Application (2015-2020)

Table 69. India Key Players Immunomodulator for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 70. India Key Players Immunomodulator for Multiple Myeloma Market Share (2019-2020)

Table 71. India Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 72. India Immunomodulator for Multiple Myeloma Market Share by Type (2015-2020)

Table 73. India Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 74. India Immunomodulator for Multiple Myeloma Market Share by Application (2015-2020)

Table 75. Central & South America Key Players Immunomodulator for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 76. Central & South America Key Players Immunomodulator for Multiple Myeloma Market Share (2019-2020)

Table 77. Central & South America Immunomodulator for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 78. Central & South America Immunomodulator for Multiple Myeloma Market Share by Type (2015-2020)

Table 79. Central & South America Immunomodulator for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 80. Central & South America Immunomodulator for Multiple Myeloma Market Share by Application (2015-2020)

Table 81. Celgene Company Details

Table 82. Celgene Business Overview

Table 83. Celgene Product

Table 84. Celgene Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 85. Celgene Recent Development

Table 86. Exova Company Details

Table 87. Exova Business Overview

Table 88. Exova Product

Table 89. Exova Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 90. Exova Recent Development

Table 91. Natco Pharma Company Details

Table 92. Natco Pharma Business Overview

Table 93. Natco Pharma Product

Table 94. Natco Pharma Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 95. Natco Pharma Recent Development

Table 96. Intas Pharmaceuticals Company Details

Table 97. Intas Pharmaceuticals Business Overview

Table 98. Intas Pharmaceuticals Product

Table 99. Intas Pharmaceuticals Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 100. Intas Pharmaceuticals Recent Development

Table 101. Indiabulls Pharmaceutical Company Details

Table 102. Indiabulls Pharmaceutical Business Overview

Table 103. Indiabulls Pharmaceutical Product

Table 104. Indiabulls Pharmaceutical Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 105. Indiabulls Pharmaceutical Recent Development

Table 106. Cipla Company Details

Table 107. Cipla Business Overview

Table 108. Cipla Product

Table 109. Cipla Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 110. Cipla Recent Development

Table 111. Glenmark Pharmaceuticals Company Details

Table 112. Glenmark Pharmaceuticals Business Overview

Table 113. Glenmark Pharmaceuticals Product

Table 114. Glenmark Pharmaceuticals Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 115. Glenmark Pharmaceuticals Recent Development

Table 116. Dr Reddy's Laboratories Business Overview

Table 117. Dr Reddy's Laboratories Product

Table 118. Dr Reddy's Laboratories Company Details

Table 119. Dr Reddy's Laboratories Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 120. Dr Reddy's Laboratories Recent Development

Table 121. Qilu Pharmaceutical Company Details

Table 122. Qilu Pharmaceutical Business Overview

Table 123. Qilu Pharmaceutical Product

Table 124. Qilu Pharmaceutical Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 125. Qilu Pharmaceutical Recent Development

Table 126. Chia Tai-Tianqing Company Details

Table 127. Chia Tai-Tianqing Business Overview

Table 128. Chia Tai-Tianqing Product

Table 129. Chia Tai-Tianqing Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 130. Chia Tai-Tianqing Recent Development

Table 131. Hanson Pharm Company Details

Table 132. Hanson Pharm Business Overview

Table 133. Hanson Pharm Product

Table 134. Hanson Pharm Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 135. Hanson Pharm Recent Development

Table 136. Meidakang Huakang Pharmaceutical Company Details

Table 137. Meidakang Huakang Pharmaceutical Business Overview

Table 138. Meidakang Huakang Pharmaceutical Product

Table 139. Meidakang Huakang Pharmaceutical Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 140. Meidakang Huakang Pharmaceutical Recent Development

Table 141. Shandong Kongfu Pharmaceutical Company Details

Table 142. Shandong Kongfu Pharmaceutical Business Overview

Table 143. Shandong Kongfu Pharmaceutical Product

Table 144. Shandong Kongfu Pharmaceutical Revenue in Immunomodulator for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 145. Shandong Kongfu Pharmaceutical Recent Development

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources



## List Of Figures

### LIST OF FIGURES

- Figure 1. Global Immunomodulator for Multiple Myeloma Market Share by Type: 2020 VS 2026
- Figure 2. Thalidomide Features
- Figure 3. Lenalidomide Features
- Figure 4. Pomalidomide Features
- Figure 5. Other Features
- Figure 6. Global Immunomodulator for Multiple Myeloma Market Share by Application: 2020 VS 2026
- Figure 7. Hospital Case Studies
- Figure 8. Drug Center Case Studies
- Figure 9. Clinic Case Studies
- Figure 10. Other Case Studies
- Figure 11. Immunomodulator for Multiple Myeloma Report Years Considered
- Figure 12. Global Immunomodulator for Multiple Myeloma Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 13. Global Immunomodulator for Multiple Myeloma Market Share by Regions: 2020 VS 2026
- Figure 14. Global Immunomodulator for Multiple Myeloma Market Share by Regions (2021-2026)
- Figure 15. Porter's Five Forces Analysis
- Figure 16. Global Immunomodulator for Multiple Myeloma Market Share by Players in 2019
- Figure 17. Global Top Immunomodulator for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immunomodulator for Multiple Myeloma as of 2019)
- Figure 18. The Top 10 and 5 Players Market Share by Immunomodulator for Multiple Myeloma Revenue in 2019
- Figure 19. North America Immunomodulator for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 20. Europe Immunomodulator for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 21. China Immunomodulator for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 22. Japan Immunomodulator for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)

Figure 23. Southeast Asia Immunomodulator for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. India Immunomodulator for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. Central & South America Immunomodulator for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Celgene Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 27. Celgene Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 28. Exova Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. Exova Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 30. Natco Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Natco Pharma Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 32. Intas Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Intas Pharmaceuticals Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 34. Indiabulls Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Indiabulls Pharmaceutical Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 36. Cipla Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Cipla Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 38. Glenmark Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Glenmark Pharmaceuticals Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 40. Dr Reddy's Laboratories Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Dr Reddy's Laboratories Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 42. Qilu Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Qilu Pharmaceutical Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 44. Chia Tai-Tianqing Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. Chia Tai-Tianqing Revenue Growth Rate in Immunomodulator for Multiple

Myeloma Business (2015-2020)

Figure 46. Hanson Pharm Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Hanson Pharm Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 48. Meidakang Huakang Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. Meidakang Huakang Pharmaceutical Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 50. Shandong Kongfu Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. Shandong Kongfu Pharmaceutical Revenue Growth Rate in Immunomodulator for Multiple Myeloma Business (2015-2020)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

Figure 54. Key Executives Interviewed

## I would like to order

Product name: COVID-19 Impact on Global Immunomodulator for Multiple Myeloma Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C499B4347FD8EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C499B4347FD8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

